Abstract
Niridazole, an antischistosomal agent, was given to renal transplant recipients in addition to azathioprine and prednisolone, as there is experimental evidence that this combination of drugs is highly immunosuppressive. Sera obtained from kidney-graft recipients during the first two weeks after transplantation were examined for their ability to inhibit the one-way mixed lymphocyte reaction (MLR). Sera from seven patients receiving azathioprine, prednisolone, and niridazole (triple-drug treatment), five patients receiving azathioprine and prednisolone, and two other patients treated with niridazole alone for schistosomiasis produced MLR inhibition by comparison with pretreatment (control) sera.
A mean of 78% inhibition was observed with sera taken after one day's treatment with the three-drug combination, whereas this level of in-vitro immunosuppression occurred only after eight days of treatment with azathioprine and prednisolone. Niridazole alone produced an effect similar to azathioprine and prednisolone. Concentrated dialysate of urine from a patient receiving triple-drug treatment not only inhibited the MLR but also significantly prolonged the survival of heterotopic heart allografts in rats, whereas dialysate from the same patient after niridazole had been stopped gave less MLR inhibition and failed to prolong heart allograft survival.
Since niridazole thus increased the in-vitro and in-vivo immunosuppressive action of azathioprine and prednisolone, we suggest that this triple-drug combination might be useful for preventing early acute kidney graft rejection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Daniels J. C., Fajardo I., David J. R. Two stages in lymphocyte mediator production by differential susceptibility to blockade using niridazole. Proc Natl Acad Sci U S A. 1975 Nov;72(11):4569–4572. doi: 10.1073/pnas.72.11.4569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Daniels J. C., Warren K. S., David J. R. Studies on the mechanism of suppression of delayed hypersensitivity by the antischistosomal compund niridazole. J Immunol. 1975 Nov;115(5):1414–1421. [PubMed] [Google Scholar]
- Eijsvoogel V. P., Du Bois R., Melief C. J., Zeylemaker W. P., Raat-Koning L., de Groot-Kooy L. Lymphocyte activation and destruction in vitro in relation to MLC and HL-A. Transplant Proc. 1973 Mar;5(1):415–420. [PubMed] [Google Scholar]
- Pelley R. P., Pelley R. J., Stavitsky A. B., Mahmoud A. A., Warren K. S. Niridazole, a potent long-acting suppressant of cellular hypersensitivity. III. Minimal suppression of antibody responses. J Immunol. 1975 Dec;115(6):1477–1482. [PubMed] [Google Scholar]
- Salaman J. R., Bird M., Godfrey A. M., Jones B., Millar D., Miller J. Prolonged allograft survival with niridazole, azathioprine, and prednisolone. Transplantation. 1977 Jan;23(1):29–32. doi: 10.1097/00007890-197701000-00005. [DOI] [PubMed] [Google Scholar]
- Webster L. T., Jr, Butterworth A. E., Mahmoud A. A., Mngola E. N., Warren K. S. Suppression of delayed hypersensitivity in schistosome-infected patients by niridazole. N Engl J Med. 1975 May 29;292(22):1144–1147. doi: 10.1056/NEJM197505292922202. [DOI] [PubMed] [Google Scholar]